INSMED Inc
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
What Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192
BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ:INSM) with a Outperform rating and announces Price Target of $192.
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients July 16, 2026 8:00 AM EDTCompany...
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
Insmed reports 12-month TPIP extension data showing sustained efficacy and favorable safety in PAH ahead of Phase 3 PALM-PAH.
Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reduction, And No Newly Identified Safety Signals In PAH
–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0––Placebo Crossed Group Demonstrated Treatment Response
Congressional Trades in $INSM
Insider Trades (Form 4)
No Form 4 insider trades found for $INSM.
Key People
No individuals linked to this entity yet.
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro